Cargando…

Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen

Mixed hepatitis C virus (HCV) genotype infection is emerging with improved methods of detection. It is commonly seen in hemodialysis patients and intravenous drug users due to repeated HCV exposure and absence of protective immunity, and can contribute to treatment failure. Direct-acting antiviral r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed Sakr, Ayman, Hanifi, Jasmine M., Valerie Lin, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Gastroenterology 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291715/ https://www.ncbi.nlm.nih.gov/pubmed/28184373 http://dx.doi.org/10.14309/crj.2017.16

Ejemplares similares

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Hepatitis C Virus Infection: Looking for Interferon Free Regimens
por: González-Moreno, J., et al.
Publicado: (2013)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation
por: Sasaki, Reina, et al.
Publicado: (2016)

Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation
por: Cholongitas, Evangelos, et al.
Publicado: (2017)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection
por: FakhriRavari, Alireza, et al.
Publicado: (2016)

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2016)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C
por: Wei, Lai, et al.
Publicado: (2019)

Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals
por: Nagao, Yumiko, et al.
Publicado: (2016)

Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China
por: Chen, Hai, et al.
Publicado: (2017)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
por: Yuen, Man-Fung, et al.
Publicado: (2020)

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens
por: Chen, Ting-Yi, et al.
Publicado: (2015)

Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital
por: del Rio-Valencia, Juan Carlos, et al.
Publicado: (2018)

The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study
por: Li, Darrick K, et al.
Publicado: (2017)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
por: Parisse, Simona, et al.
Publicado: (2023)

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon
por: D’Ambrosio, Roberta, et al.
Publicado: (2016)

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen
por: Chen, Ruiqi, et al.
Publicado: (2020)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
por: Ramos, Huascar, et al.
Publicado: (2017)

Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b
por: Endo, Daisuke, et al.
Publicado: (2017)

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1
por: Linas, Benjamin P., et al.
Publicado: (2016)

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice
por: Papatheodoridi, Μargarita, et al.
Publicado: (2017)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
por: Babatin, Mohammed A., et al.
Publicado: (2019)

Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
por: Ferreira, Vinicius Lins, et al.
Publicado: (2020)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

Increase in Free Hepatic Venous Pressure Response to Beta-Blockers Predicts Variceal Bleeding in Cirrhotic Patients
por: Guo, Huiwen, et al.
Publicado: (2021)

The response of hepatitis B virus genotype to interferon is associated with a mutation in the interferon-stimulated response element
por: Guo, Yanan, et al.
Publicado: (2019)

Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes
por: Lang Kuhs, Krystle A., et al.
Publicado: (2015)

Hepatic Cavernous Hemangioma in Cirrhotic Liver: Imaging Findings
por: Yu, Jeong-Sik, et al.
Publicado: (2000)

Hepatic manifestations and impact of COVID-19 on the cirrhotic patient()
por: Velarde-Ruiz Velasco, J.A., et al.
Publicado: (2020)

Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
por: Patankar, Sayalee, et al.
Publicado: (2023)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Usage of Direct Acting Oral Anticoagulants in Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: A Systematic Review
por: Gupta, Sachin, et al.
Publicado: (2021)

Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
por: Venugopal, Vishnu, et al.
Publicado: (2018)

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
por: Al Moussawi, Hassan, et al.
Publicado: (2018)

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients
por: Ali, Bushra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_48nvpb9imrbh923o308fh8t83u